These ASX blue chips now look too cheap to ignore

These blue chips could be worth a closer look after sharp declines.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It is not often that high-quality blue chip shares trade at discounted valuations. These are typically businesses with strong competitive advantages, global earnings, and long track records of performance.

But from time to time, even the best companies fall out of favour.

Right now, a handful of ASX blue chips appear to be in that position. Here are three that could be worth a closer look.

A man looking at his laptop and thinking.

Image source: Getty Images

CSL Ltd (ASX: CSL)

CSL is widely regarded as one of Australia's highest-quality companies, but the biotech giant's shares have come under pressure in recent times.

This has been driven by earnings misses, margin pressures, a tough operating environment, and leadership changes.

However, these are largely transitional issues rather than structural ones.

CSL still operates a global leader in plasma therapies and vaccines, with strong demand drivers linked to ageing populations and rising healthcare needs. As plasma collection normalises and efficiencies improve, there is potential for margins to recover.

For long-term investors, this could be one of those rare opportunities to buy a premium healthcare business at a more reasonable price.

Cochlear Ltd (ASX: COH)

Another ASX blue chip that could be looking attractive is Cochlear.

Short-term concerns around softer demand have weighed on sentiment. But this does not change the underlying demand for hearing solutions.

Cochlear benefits from a powerful structural tailwind. Hearing loss is a growing global issue, and access to treatment is still underpenetrated in many regions.

The company also enjoys a strong competitive position, supported by technology leadership and a global distribution network.

For investors willing to look beyond near-term noise, Cochlear's long-term growth story appears firmly intact.

Treasury Wine Estates Ltd (ASX: TWE)

A third ASX blue chip that may be undervalued is Treasury Wine Estates.

The company has faced a number of challenges in recent years, including shifting consumer preferences and disruptions to key export markets. These issues have weighed on its share price and created uncertainty around its outlook.

However, Treasury Wine is in the process of reshaping its portfolio.

The focus is increasingly on premium and luxury brands, where margins are higher and demand tends to be more resilient. This shift is helping the company reduce reliance on lower-margin products and improve the quality of its earnings.

In addition, improving trade dynamics and stabilising conditions in key markets could provide a tailwind over time.

While not without risks, Treasury Wine Estates could offer a compelling turnaround opportunity for patient investors.

Motley Fool contributor James Mickleboro has positions in CSL, Cochlear, and Treasury Wine Estates. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, and Treasury Wine Estates. The Motley Fool Australia has positions in and has recommended Treasury Wine Estates. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Young woman thinking with laptop open.
Blue Chip Shares

Why is everyone selling Wesfarmers shares?

It looks like the retail conglomerate fell out of favour with investors this year.

Read more »

Four business people wearing formal business suits and ties walk abreast on a wide paved surface with their long shadows falling on the ground ahead of them.
Blue Chip Shares

How did these ASX blue-chip shares perform in March?

Did these blue-chips beat the market in March?

Read more »

Couple looking at their phone surprised, symbolising a bargain buy.
Blue Chip Shares

Are these ASX blue chips now too cheap to ignore?

Let's see why these shares could be seriously undervalued at current levels.

Read more »

A woman gives two fist pumps with a big smile as she learns of her windfall, sitting at her desk.
Blue Chip Shares

3 reasons to buy Wesfarmers shares today

The retail conglomerate is a no-brainer buy in my book.

Read more »

ASX shares buy Street signs stating 'Winners' and 'Losers' in front of urban backdrop
Blue Chip Shares

How are these 5 ASX share giants really tracking in 2026?

Some are struggling, while others are thriving, proving that opportunity is never far away.

Read more »

Happy work colleagues give each other a fist pump.
Blue Chip Shares

My best blue-chip ASX 200 buys for April

Looking for quality in uncertain markets? These three ASX 200 shares stand out to me.

Read more »

A woman scratches her head, thinking is this a no-brainer?
Healthcare Shares

Does this ASX 200 stock's fall make it a no-brainer buy?

Despite a major transformation, this stock is down more than 20%. Is this an opportunity?

Read more »

A happy woman stands outside a building looking at her phone and smiling widely.
Blue Chip Shares

I think smart investors should buy these ASX 200 blue-chip shares with $10,000

Looking for ideas? Here are three ASX 200 blue chips that could help build long-term wealth.

Read more »